Dubai: Agiomix FZ-LLC; the next generation sequencing and molecular genetics lab in Dubai received its Dubai Health Authority (DHA) license on 18th June 2019, the lab at the Dubai Science Park was inspected by the DHA team for quality and compliance with the DHA licensing requirements and was found to be in conformance with all the required policies, guidelines and regulations to receive the DHA license.
The DHA licensing process is designed to ensure onsite facility design, quality of services, and safety of the professionals in accordance with the local laws whilst maintaining international quality standards of service. The Authority examines and scrutinizes all aspects of offering healthcare service, such as laboratory protocols, equipment, staff, safety programs, record ensure compliance with DHA regulatory requirements, and the United Arab Emirates (UAE) federal laws.
Following this successful licensing, Dr. Walid Dridi, the Medical Director of Agiomix said, “This is a great step of confirmation of our internal quality standards, it also gives us the opportunity to start serving the populations of the United Arab Emirates and the region with our genetic and molecular assays and services.”
About Agiomix FZ-LLC
Agiomix FZ-LLC is a Dubai-headquartered genomics company, focused on offering sequencing and genotyping services to research and clinical customers. Agiomix strives to offer localized, high standard and affordable genomics analysis services with unparalleled counseling and support.
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
